MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

Search

CRISPR Therapeutics AG

Închisă

SectorSănătate

68.77 0.61

Rezumat

Modificarea prețului

24h

Curent

Minim

68.01

Maxim

69.53

Indicatori cheie

By Trading Economics

Venit

-73M

-209M

Vânzări

27K

892K

Marjă de profit

-23,379.933

Angajați

393

EBITDA

-59M

-203M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+1.53% upside

Dividende

By Dow Jones

Următoarele câștiguri

4 nov. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

1.1B

6.2B

Deschiderea anterioară

68.16

Închiderea anterioară

68.77

Sentimentul știrilor

By Acuity

53%

47%

292 / 371 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

CRISPR Therapeutics AG Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

17 oct. 2025, 18:13 UTC

Principalele dinamici ale pieței

Revolution Medicines Rises as FDA Grants Priority Designation for Cancer Treatment

17 oct. 2025, 17:05 UTC

Principalele dinamici ale pieței

Artiva Biotherapeutics Shares Jump After Treatment Gets Fast Tracked

18 oct. 2025, 13:30 UTC

Achiziții, Fuziuni, Preluări

Deal Expected to Value Unit at Roughly $4B, Sources Say -- WSJ

18 oct. 2025, 13:30 UTC

Achiziții, Fuziuni, Preluări

Deal Could Be Announced as Soon as Next Week, Sources Say -- WSJ

18 oct. 2025, 13:30 UTC

Achiziții, Fuziuni, Preluări

Gucci Owner Kering Nears $4 Billion Sale of Beauty Unit to L'Oréal -- WSJ

18 oct. 2025, 13:30 UTC

Achiziții, Fuziuni, Preluări

Gucci Parent Kering in Talks to Sell Beauty Business to L'Oréal, Sources Say -- WSJ

18 oct. 2025, 08:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

17 oct. 2025, 23:25 UTC

Achiziții, Fuziuni, Preluări

New Zealand's 'Golden Visa' Targets the Affluent in Search of Plan B -- Barrons.com

17 oct. 2025, 22:15 UTC

Market Talk

Ulta's CFO Appointment Seen Supporting Growth -- Market Talk

17 oct. 2025, 21:15 UTC

Market Talk

Greece Expected to Post Overall Budgetary Surplus This Year -- Market Talk

17 oct. 2025, 21:07 UTC

Market Talk

Oracle Stock Expected to Take a Breather as Capex Climbs -- Market Talk

17 oct. 2025, 21:07 UTC

Market Talk

Global Equities Roundup: Market Talk

17 oct. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17 oct. 2025, 20:34 UTC

Market Talk

Deere Is Reaching the End of Its Downcycle -- Market Talk

17 oct. 2025, 20:27 UTC

Market Talk

Soft Growth Ahead in Canada But Not Far Off From Potential GDP, Macklem Says -- Market Talk

17 oct. 2025, 19:46 UTC

Market Talk

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

17 oct. 2025, 19:45 UTC

Market Talk

Oil Futures Stabilize, But End Week With A Loss -- Market Talk

17 oct. 2025, 18:45 UTC

Market Talk

Treasury Yields, Dollar Try to Reclaim Some Ground -- Market Talk

17 oct. 2025, 17:51 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 oct. 2025, 17:51 UTC

Market Talk

Euro Still a Long Way From Supplanting Dollar, Former ECB Rate Setter Says -- Market Talk

17 oct. 2025, 17:44 UTC

Market Talk

EQT Seen With Long-Term Growth Opportunities -- Market Talk

17 oct. 2025, 17:35 UTC

Market Talk

U.S. Oil Rig Count Unchanged at 418 -- Market Talk

17 oct. 2025, 16:20 UTC

Market Talk
Câștiguri

Tech, Media & Telecom Roundup: Market Talk

17 oct. 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

17 oct. 2025, 16:14 UTC

Market Talk

Home Depot Will Gain From Pick Up in Home Improvement Activity -- Market Talk

17 oct. 2025, 16:04 UTC

Market Talk

Home Improvement Demand Is Starting to Pick Up -- Market Talk

17 oct. 2025, 15:58 UTC

Market Talk

Amazon's Project Rainier Will Begin to Stem Its AI Share Losses -- Market Talk

17 oct. 2025, 15:56 UTC

Câștiguri

These Stocks Are Moving the Most Today: Zions Bancorp, Jefferies, Amex, Oracle, Novo Nordisk, Lilly, State Street, CSX, and More -- Barrons.com

17 oct. 2025, 15:43 UTC

Market Talk

Global Equities Roundup: Market Talk

17 oct. 2025, 15:43 UTC

Market Talk

Amazon's Earnings Are About Sentiment of Consumers, Not Investors -- Market Talk

Comparație

Modificare preț

CRISPR Therapeutics AG Așteptări

Obiectiv de preț

By TipRanks

1.53% sus

Prognoză pe 12 luni

Medie 70.21 USD  1.53%

Maxim 99 USD

Minim 40 USD

În baza a 17 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruCRISPR Therapeutics AG - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

17 ratings

11

Cumpărare

6

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

33.5 / 38.27Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Strong Bearish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

292 / 371 Clasament în Sănătate

Sentimentul știrilor

Evidențe de scădere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre CRISPR Therapeutics AG

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease, and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting CD19 and CTX131 targeting CD70 for oncology and autoimmunune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and VCTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
help-icon Live chat